Richard Jennemann

4PUBLICATIONS
7CO-AUTHORS
Biomolecular modelling and designMolecular targetsNeurology and neuromuscular diseasesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Oct 16, 2025
The SGLT2 Inhibitor Dapagliflozin Disrupts the Cell Cycle at High Concentrations Without Altering Glycosphingolipid (De Novo)Biosynthesis.

Richard Jennemann, Roger Sandhoff

|Jan 11, 2025
Glucosylceramide Synthase Inhibition in Combination with Aripiprazole Sensitizes Hepatocellular Cancer Cells to Sorafenib and Doxorubicin.

Richard Jennemann, Martina Volz, Roberto Carlos Frias-Soler

|Dec 23, 2022
GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype.

Claudia Paret, Arsenij Ustjanzew, Sara Ersali

|Oct 13, 2021
Blockade of Glycosphingolipid Synthesis Inhibits Cell Cycle and Spheroid Growth of Colon Cancer Cells In Vitro and Experimental Colon Cancer Incidence In Vivo.

Richard Jennemann, Martina Volz, Felix Bestvater

Pageof 1

Frequent Collaborators

1 joint publications

Karsten Richter

1 joint publications

Johannes Müthing

1 joint publications

Roger Sandhoff

1 joint publications

Claudia Paret